These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27461515)

  • 1. Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.
    Pettai K; Milani L; Tammiste A; Võsa U; Kolde R; Eller T; Nutt D; Metspalu A; Maron E
    Eur Neuropsychopharmacol; 2016 Sep; 26(9):1475-1483. PubMed ID: 27461515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid autoimmunity and treatment response to escitalopram in major depression.
    Eller T; Metsküla K; Talja I; Maron E; Uibo R; Vasar V
    Nord J Psychiatry; 2010 Aug; 64(4):253-7. PubMed ID: 20088751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.
    Maron E; Tammiste A; Kallassalu K; Eller T; Vasar V; Nutt DJ; Metspalu A
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):451-6. PubMed ID: 19272758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.
    Papiol S; Arias B; Gastó C; Gutiérrez B; Catalán R; Fañanás L
    J Affect Disord; 2007 Dec; 104(1-3):83-90. PubMed ID: 17467808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
    Li H; Li T; Li G; Luo J
    Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder.
    Leuchter AF; Cook IA; Gilmer WS; Marangell LB; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):132-8. PubMed ID: 19709754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
    Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
    Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of escitalopram and severity of depression: new data].
    Spadone C
    Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.
    Baskaran A; Farzan F; Milev R; Brenner CA; Alturi S; Pat McAndrews M; Blier P; Evans K; Foster JA; Frey BN; Giacobbe P; Lam RW; Leri F; MacQueen GM; Müller DJ; Parikh SV; Rotzinger S; Soares CN; Strother SC; Turecki G; Kennedy SH;
    J Affect Disord; 2018 Feb; 227():542-549. PubMed ID: 29169123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram plasma levels and antidepressant response.
    Florio V; Porcelli S; Saria A; Serretti A; Conca A
    Eur Neuropsychopharmacol; 2017 Sep; 27(9):940-944. PubMed ID: 28648553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    Montgomery SA; Möller HJ
    Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
    Wang P; Lv Q; Mao Y; Zhang C; Bao C; Sun H; Chen H; Yi Z; Cai W; Fang Y
    J Affect Disord; 2018 Mar; 228():222-228. PubMed ID: 29275155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.